A stereochemically-constrained enkephalin analog α-Aminoisobutyryl2 methionine5 enkephalinamide by Nagaraj, R. & Balaram, P.
Volume 96, number 2 FEBS LETTERS December 1978 
A STEREOCHEMICALLY-CONSTRAINED ENKEPHALIN ANALOG 
a-Aminoisobutyryl’ methionine’ enkephalinamide 
R. NAGARAJ and P. BALARAM+ 
Molecular Biophysics Unit and Solid State and Structural Chemistry Unit, Indian Institute of Science, 
Bangalore 560012, India 
Received 14 August 1978 
1. Introduction 
The discovery that the pentapeptides Tyr-Gly- 
Gly-Phe-Met (Met’-enkephalin) and Tyr-Gly- 
Gly-Phe-Leu @us-enkephalin), present in the mam- 
malian central nervous system [ 1,2], possess opioid 
activity has stimulated considerable interest in their 
conformations [3-151. The enkephalins have been 
shown to bind to the opiate receptor in brain and 
displace naloxone, a powerful opiate antagonist [ 161. 
The structures of the enkephalins have been the sub- 
ject of a number of spectroscopic and theoretical 
investigations. There have been attempts to build a 
structural model for the pentapeptides that mimics 
the essential features of the morphine molecule 
[S-l 11. From these studies conflicting suggestions 
have emerged about the low energy conformation 
of enkephalins and also the possible conformation 
of the pentapeptides at the opiate receptor site. A 
single crystal X-ray diffraction study of [Leu’] 
enkephalin has been reported [ 171, in which the 
molecule has been shown to possess a Gly2-Gly3 
@turn stabilised by two intramolecular hydrogen 
bonds between the CO and NH groups of Tyr’ and 
the NH and CO groups of Phe4. This conformation 
has not been suggested by any of the spectroscopic 
or theoretical studies, though it was put forward 
earlier on the basis of empirical predictive proce- 
dures [9]. The presence of two glycine residues in 
enkephalin is likely to result in enhanced flexibility 
of the peptide backbone in solution. Consequently 
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nuclear magnetic resonance (NMR) investigations 
may be confronted with the problem of dynamic 
averaging, between conformers of similar energies. 
The substitution of the Ca hydrogen atoms with alkyl 
residues in peptides, restricts conformational freedom. 
Experimental [l&20] and theoretical [21-231 
studies have shown that the dimethyl analog of 
glycine, H2N- (CH,),-COOH, (cu-aminoisobutyric 
acid, Aib) is an extremely sterically hindered amino 
acid capable of occupying only a small region of 
conformational space (@ - f 60”, $ - + 304 in the 
right- or left-handed 310 or a-helical regions of the 
conformational map [24]. Substitution of the glycine 
residues in enkephalin with cu-aminoisobutyric acid 
residues should then lead to analogs with fewer 
conformational possibilities. We describe here the 
synthesis of the stereochemically-constrained 
enkephalin analog, [Aib2 Mets] enkephalinamide (I). 
2. Experimental 
Amino acid methyl esters were prepared by the 
thionyl chloride-methanol procedure [25] while 
t-butyloxycarbonyl (Boc) amino acids were pre- 
pared as in [26]. The coupling reactions were 
carried out using dicyclohexylcarbodiimide (DCC). 
Removal of the Boc protecting groups were effected 
using HCl/tetrahydrofuran. The synthetic scheme is 
outlined in fig.1. [Aib’ Mets] enkephalinamide was 
obtained as a white solid, thin-layer chromatography 
on Silica gel, RF = 0.57 (n-butanol-acetic acid- 
water, 4: 1 : 1). A faint ninhydrin negative spot at 
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Fig.1. Synthetic scheme for the preparation of [Aib’ Met’] 
enkephalinamide. 
RF = 0.83 was also noted. Ultraviolet (methanol) 
x = 276 nm. On addition of NaOH h,, was 
sGf%d to 296 nm (tyrosine absorption). Satisfactory 
270 MHz ‘H NMR spectra, in accordance with the 
structure were obtained on a Brucker WH-270 Fourier 
Transform NMR Spectrometer, at the Bangalore 
NMR Facility. 
3. Results and discussion 
The 270 MHz ‘H NMR spectrum of I in (CD&SO 
is shown in fig.2. The assignments of the resonances are 
indicated. It is interesting to note that the CaHz pro- 
tons of Gly3 are non-equivalent and appear as the AB 
part of an ABX spectrum centred at -3.6 6. The two 
methyl groups of Aib2 are also non-equivalent as 
evidenced by the resonances at 1.38 6 and 1.40 6. 
Earlier studies have shown that the C”H2 protons of 
both Gly* and Gly3 in Mets-enkephalin are non- 
equivalent m Hz0 and (CD,),SO, suggesting that the 
molecules are inflexible on a chemical shift time 
scale. Non-equivalence of the C&H2 protons of Gly 
residues has also been used to support the view that 
ordered conformations exist in solution, for a tetra- 
peptide fragment of tropoelastin Boc-Val-Pro- 
Gly-Gly-OMe [27]. While geminal non-equivalance 
of the C&H2 protons of Gly3 and the CH3 groups of 
Aib*, is not conclusive evidence for the presence of 
I-‘lg.2. 270 MHz ‘H NMR spectrum of I in (CD,),SO. Chemical 
shifts are expressed as 6 (ppm) downfield from TMS. Tyr 
‘ortho’ and ‘meta are the protons ortho and meta to the 
hydroxyl group. Peaks marked with an asterix are due to 
impurities. 
ordered structures, it is likely that I adopts fairly well 
defined conformations in solution. 
Preliminary studies indicate that I possesses high 
analgesic activity in rats, suggesting that the confor- 
mations necessary for receptor binding are still 
accessible in the Aib’ analog. D-Ala* -enkephalina- 
mide [28,29] is a potent long lasting analgesic with 
a high affinity for the opiate receptor whereas the 
L-Ala analog exhibits only weak receptor binding. 
These results suggest hat the conformations permis- 
sible for the D-Ala and Aib residues fit the opiate 
receptor whereas the conformations adopted by the 
L-Ala residue are unfavourable for receptor interac- 
tions. Theoretical studies [30] have shown that pep- 
tide sequences with alternating configurations (DL 
or LD) have a high probability of forming p-turns 
[31]. cY-Aminoisobutyric acid residues have also 
been shown to have a very strong tendency to initi- 
ate the formation of p-turns. from X-ray diffraction 
and spectroscopic investigations of Aib-containing 
peptides [ 18-201. It is significant that the solid state 
conformation of Leus-enkephalin possesses ap-turn 
with Gly2 and Gly3 as the central residues [ 171. A 
conformation that is accessible to all three active 
enkephalin analogs involves the p-turn with residues 
2 and 3 at the corners. It is likely that binding to the 
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opiate receptor can then be accomplished by reorien- 
tation of the Tyr and Phe sidechains. 
The torsional angles allowed for residue 2 as judged 
by the activity of the D-Ala’ and Aib* analogs is 
restricted to the region 4 -60” and $ -3O”, since the 
Aib residue is energetically confined largely to the 
regions @ - f 60” and $ - ? 30”. It is noteworthy 
that the values obtained in the X-ray study [ 171 for 
Gly* are q5 = 59” and I) = 25”. Based on computer 
modelling studies the D-Ala residue in D-Ala’-enke- 
phalinamide has been suggested to have r$ = 160” 
and J, = -87” in the conformation involved in recep- 
tor binding [32]. These values of 4 and $ would 
lead to a very high energy for the Aib* analog, which 
is unlikely to be offset by binding interactions at the 
opiate receptor. The backbone conformation at the 
receptor site is therefore unlikely to involve large 
departures from the p-turn involving residues 3 and 
3. The judicious use of cu-alkyl amino acid residues in 
preparing synthetic analogs may allow a better defi- 
nition of the biologically active conformation. 
Further studies on the synthesis of the Aib* and 
[Aib’ Aib3] enkephalin analogs and studies of their 
c’onformations and biological activity are in pro- 
gress. 
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